Isomorphic Labs has raised 5 billion US dollars: on 17 November 2026, the London-based AI drug design company announced a Series C financing round. It was co-led by Greenoaks and Sequoia Capital, new investors include Andreessen Horowitz (a16z), and Alphabet is again investing significantly. The company, led by Demis Hassabis, wants to use the money to move its first in-house drug candidates into clinical trials.
Isomorphic Labs: the key facts of the round
According to the Isomorphic Labs press release, the round was oversubscribed. Besides the two lead investors and a16z, several other new backers joined, along with all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. GV and CapitalG are Alphabet’s venture arms.
The company did not disclose a valuation. TechCrunch points to a Bloomberg report from earlier in November saying Isomorphic was seeking a valuation of 50 billion dollars. That figure is not confirmed. The round comes only about six months after a 2.1 billion dollar Series B in May.
For the sector, the amount is exceptional. Trade outlet BioPharma Dive writes that the company’s two rounds this year are the largest venture financings among the 26 companies it tracks in this segment. It adds that the Series C is the largest financing it has recorded since 2022.
What IsoDDE is
At the heart of the business is a proprietary drug design platform called IsoDDE (Isomorphic Drug Design Engine). According to the company, it combines a suite of foundational simulation models that work across multiple therapeutic areas and drug modalities. The models explore vast chemical spaces to design and refine molecules with optimal drug-like properties.
Isomorphic says these models are complemented by proprietary AI agents that “navigate and reason over” complex biological systems. The release claims the simulation models push predictions towards experimental accuracy. It does not cite studies or data to back this up – these are company claims.
The reference to multiple modalities matters. Drug research distinguishes, for example, between small molecules, the kind found in conventional tablets, and larger biologics such as antibodies. Each follows different chemical rules and development paths. A toolkit that works across these boundaries is meant to let Isomorphic choose the right type of drug for a given disease target rather than committing to one class. The release does not specify which modalities IsoDDE covers.
Isomorphic Labs was founded in 2021 as a spin-out from Google’s AI lab DeepMind. Its work builds on AlphaFold, the protein structure prediction system for which Hassabis and John Jumper received the Nobel Prize in Chemistry. According to TechCrunch, the Series C is the first raise since Hassabis gave up his role as head of DeepMind to focus on drug discovery. He is now chairman of DeepMind.
What the money is for
The release lists several goals:
- Develop IsoDDE further and expand deeper into “new biology” with advanced models.
- Build a partner ecosystem to better understand the mechanisms of disease.
- Build global infrastructure for AI-led bioengineering.
- Expand AI-first translational and clinical development to move drug candidates into clinical trials.
The company gives no figures on how the money will be split, on individual programmes or on a timeline for trials. Which diseases the first candidates target also remains open. All that is known is that internal programmes in oncology and immunology have produced positive preclinical results, as have partnered programmes. According to Isomorphic, this sets the stage for clinical entry.
Partners and competition
Isomorphic works with large pharmaceutical companies, according to TechCrunch and BioPharma Dive including Eli Lilly, Novartis and Johnson & Johnson. The company says its portfolio consists of partnered programmes and wholly owned internal programmes. The internal programmes matter most for its value, because Isomorphic keeps most of the upside there but also carries the full development risk.
The market is moving. BioPharma Dive names Bristol Myers Squibb, Merck & Co., Eli Lilly and Novo Nordisk as companies that announced significant AI investments or partnerships this year. AI labs are pushing into the field too: Anthropic recently presented early results from Claude in drug development, and language models increasingly appear in basic research, for example in the discovery of a CRISPR-like enzyme system.
What the people involved say
Hassabis said in the release that when Isomorphic was founded, the conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI. The engine is generating molecules “with unprecedented precision and speed”, he said, and the round will help drive the first therapeutic programmes towards clinical trials.
President Max Jaderberg said the models deliver repeatable scientific advances “every week” that translate directly into better molecular profiles. The investors are, as expected, upbeat: Neil Mehta of Greenoaks calls drug development “an optimization challenge of almost infinite scale”, while Konstantine Buhler of Sequoia speaks of foundational technology for the future of medicine.
Analysis
The round shows that investors are still prepared to commit large sums to AI applications with a clear domain focus – even at a time when the AI industry as a whole is under pressure. BioPharma Dive points to the sell-off in technology stocks and the turmoil around Nvidia’s leadership change.
At the same time, the central question remains unanswered: whether AI-designed molecules actually perform better in clinical trials than conventionally developed ones. BioPharma Dive notes that no AI-designed medicine has been approved so far and that even proponents warn against excessive expectations. Preclinical success is a necessary but not sufficient step; many drug candidates fail only in clinical trials, when efficacy and safety have to be shown in humans.
For Isomorphic Labs, this marks the start of the phase in which its platform must be judged on hard results. 5 billion dollars buys a lot of time for that. When the first trials will start, and with which candidates, the company has not yet said. More details are available on the Isomorphic Labs website.




